Search Results - "Merola, J. F."

Diagnosing and treating psoriatic arthritis: an update by Boehncke, W.H., Qureshi, A., Merola, J.F., Thaçi, D., Krueger, G.G., Walsh, J., Kim, N., Gottlieb, A.B.

“…Summary Psoriatic arthritis (PsA) is an inflammatory arthritis of uncertain pathogenesis, affecting approximately one in four patients with psoriasis. Onset of…”
Get full text

Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measures by Skougaard, M, Stisen, ZR, Jørgensen, TS, Egeberg, A, Hansen, RL, Perez-Chada, LM, Mogensen, M, Merola, JF, Gerwien, JG, Kristensen, LE

“…To examine the prevalence of sleep disturbances, quantified by the Pittsburgh Sleep Quality Index (PSQI), in patients with psoriatic arthritis (PsA), psoriasis…”
Get full text

Cigarette smoking, alcohol consumption and risk of systemic lupus erythematosus by Takvorian, SU, Merola, JF, Costenbader, KH

“…Systemic lupus erythematosus (SLE) is a complex multisystem autoimmune disease whose pathogenesis is thought to involve both genetic and environmental factors…”
Get full text

Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II by Thorlacius, L., Garg, A., Ingram, J.R., Villumsen, B., Theut Riis, P., Gottlieb, A.B., Merola, J.F., Dellavalle, R., Ardon, C., Baba, R., Bechara, F.G., Cohen, A.D., Daham, N., Davis, M., Emtestam, L., Fernández‐Peñas, P., Filippelli, M., Gibbons, A., Grant, T., Guilbault, S., Gulliver, S., Harris, C, Harvent, C., Houston, K., Kirby, J.S., Matusiak, L., Mehdizadeh, A., Mojica, T., Okun, M., Orgill, D., Pallack, L., Parks‐Miller, A., Prens, E.P., Randell, S., Rogers, C., Rosen, C.F., Choon, S.E., Zee, H.H., Christensen, R., Jemec, G.B.E.

“…Summary Background A core outcomes set (COS) is an agreed minimum set of outcomes that should be measured and reported in all clinical trials for a specific…”
Get full text

Mosaic focal dermal hypoplasia caused by a novel somatic mutation in PORCN detected in affected skin by Sheu, J., Divito, S.J., Hoffman, E.P., Frank, N.Y., Merola, J.F.

Get full text

Clinical manifestations and survival among adults with (SLE) according to age at diagnosis by Merola, JF, Bermas, B, Lu, B, Karlson, EW, Massarotti, E, Schur, PH, Costenbader, KH

“…Objectives The objective of this paper is to determine the effect of clinical and laboratory manifestations, and medication prescribing, on survival according…”
Get full text

Psoriatic arthritis screening tools: study design and methodological challenges by Merola, J.F., Husni, M.E., Qureshi, A.A.

Get full text

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis by Wu, J.J., Kavanaugh, A., Lebwohl, M.G., Gniadecki, R., Merola, J.F.

“…Psoriasis is a chronic systemic inflammatory disorder associated with several comorbidities in addition to the characteristic skin lesions. Metabolic syndrome…”
Get full text

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process by Thorlacius, L., Ingram, J.R., Villumsen, B., Esmann, S., Kirby, J.S., Gottlieb, A.B., Merola, J.F., Dellavalle, R., Nielsen, S.M., Christensen, R., Garg, A., Jemec, G.B.E.

“…Summary Background There is no consensus on core outcome domains for hidradenitis suppurativa (HS). Heterogeneous outcome measure instruments in clinical…”
Get full text

Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey by Gondo, G.C., Merola, J.F., Bell, S.J., Blauvelt, A.

Get full text

Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study by Gottlieb, A.B., Merola, J.F., Reich, K., Behrens, F., Nash, P., Griffiths, C.E.M., Bao, W., Pellet, P., Pricop, L., McInnes, I.B.

“…Summary Background Secukinumab [an interleukin (IL)‐17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor…”
Get full text

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis by Ryan, C., Menter, A., Guenther, L., Blauvelt, A., Bissonnette, R., Meeuwis, K., Sullivan, J., Cather, J.C., Yosipovitch, G., Gottlieb, A.B., Merola, J.F., Callis Duffin, K., Fretzin, S., Osuntokun, O.O., Burge, R., Naegeli, A.N., Yang, F.E., Lin, C.‐Y., Todd, K., Potts Bleakman, A.

“…Summary Background Genital psoriasis (GenPs) is a common, debilitating and difficult‐to‐treat manifestation of plaque psoriasis. However, few controlled,…”
Get full text

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3) by Menter, A., Warren, R.B., Langley, R.G., Merola, J.F., Kerr, L.N., Dennehy, E.B., Shrom, D., Amato, D., Okubo, Y., Reich, K.

“…Background Palmoplantar psoriasis has significant physical and emotional impact on patients and can be difficult to treat. Objective To evaluate the efficacy…”
Get full text

Redefining cutaneous lupus erythematosus: a proposed international consensus approach and results of a preliminary questionnaire by Merola, J F, Nyberg, F, Furukawa, F, Goodfield, M J, Hasegawa, M, Marinovic, B, Szepietowski, J, Dutz, J, Werth, V P

“…There is currently no uniform definition of cutaneous lupus erythematosus (CLE) upon which to base a study population for observational and interventional…”
Get full text

Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies by Bachelez, H., Griffiths, C. E. M., Papp, K. A., Hall, S., Merola, J. F., Feldman, S. R., Khraishi, M., Tan, H., Fallon, L., Cappelleri, J. C., Bushmakin, A. G., Young, P.

Get full text

Risk of connective tissue disease, morphoea and systemic vasculitis in patients with hidradenitis suppurativa by Schneeweiss, M.C., Merola, J.F., Schneeweiss, S., Wyss, R., Rosmarin, D.

“…Background Hidradenitis suppurativa (HS) has been associated with auto‐inflammatory conditions, yet the risk of developing connective tissue disease (CTD),…”
Get full text

Indoor tanning use is associated with psoriasis in the Nurses’ Health Study II by Choong, C.K., Merola, J.F., Han, J., Li, X.

Get full text

Prevalence of psoriasis phenotypes among men and women in the USA by Merola, J. F., Li, T., Li, W.-Q., Cho, E., Qureshi, A. A.

“…Summary Background We present the largest set of US prevalence data for psoriasis to date, obtained from three prospective cohort studies describing validated…”
Get full text

Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease‐associated calcinosis cutis by Song, P., Fett, N.M., Lin, J., Merola, J.F., Costner, M., Vleugels, R.A.

“…Summary Dystrophic calcinosis cutis is a debilitating condition of calcium salt deposition in the skin often occurring in association with connective tissue…”
Get full text

Older adults on systemic treatment for psoriasis and risk of infection: a propensity score‐matched population‐based study by Schneeweiss, M.C., Perez Chada, L., Gottlieb, A.B., Merola, J.F.

Get full text